Xenon Pharmaceuticals Inc.
XENE
22 insider filings · Latest: Oct 15, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Oct 1 1:20 PM | Thomas Patrick KellyChief Financial Officer | Purchase | 15,000 | $37.32 | $559.7K | 15,000(D) | View → |
| Sep 30, 2026 | Oct 1 1:19 PM | Ian MortimerDirector, PRESIDENT & CEO | Purchase | 30,000 | $37.38 | $1.1M | 49,923(D) | View → |
| Aug 28, 2026 | Sep 1 1:59 AM | Christopher John KenneyChief Medical Officer | Sale | 7,068 | $60.25 | $425.8K | 2(D) | View → |
| Aug 28, 2026 | Aug 28 8:25 PM | CHRISTOPHER KENNEY | Proposed Sale | 7,068 | $61.93 | $437.7K | — | View → |
| Aug 11, 2026 | Aug 13 8:33 PM | Steven GannonDirector | Sale | 10,000 | $64.06 | $640.6K | 1,870(D) | View → |
| Aug 11, 2026 | Aug 13 8:30 PM | STEVEN GANNON | Proposed Sale | 10,000 | $64.06 | $640.6K | — | View → |
| Jun 5, 2026 | Jun 9 1:19 AM | Gary PatouDirector | Sale | 1,322 | $53.14 | $70.3K | 24,896(D) | View → |
| Jun 5, 2026 | Jun 9 1:19 AM | Gillian CannonDirector | Sale | 1,190 | $53.14 | $63.2K | 1,455(D) | View → |
| Jun 5, 2026 | Jun 5 8:32 PM | GILLIAN CANNON | Proposed Sale | 1,190 | $52.99 | $63.1K | — | View → |
| Jun 5, 2026 | Jun 5 8:32 PM | GARY PATOU | Proposed Sale | 1,322 | $52.99 | $70.1K | — | View → |
| Mar 13, 2026 | Mar 14 12:16 AM | Christopher John KenneyChief Medical Officer | Sale | 1,410 | $55.23 | $77.9K | 7,069(D) | View → |
| Mar 13, 2026 | Mar 14 12:16 AM | Andrea DifabioChief Legal Officer | Sale | 1,342 | $55.23 | $74.1K | 7,301(D) | View → |
| Mar 13, 2026 | Mar 14 12:16 AM | Ian MortimerDirector, PRESIDENT & CEO | Sale | 7,308 | $55.23 | $403.6K | 19,923(D) | View → |
| Mar 13, 2026 | Mar 13 11:51 PM | CHRISTOPHER JOHN KENNEY | Proposed Sale | 1,410 | $55.22 | $77.9K | — | View → |
| Mar 13, 2026 | Mar 13 11:50 PM | ANDREA DIFABIO | Proposed Sale | 1,342 | $55.23 | $74.1K | — | View → |
| Mar 13, 2026 | Mar 13 11:49 PM | IAN MORTIMER | Proposed Sale | 7,308 | $55.22 | $403.6K | — | View → |
| Mar 10, 2026 | Mar 11 11:21 PM | Christopher John KenneyChief Medical Officer | Sale | 2,771 | $60.11 | $166.6K | 4,729(D) | View → |
| Mar 10, 2026 | Mar 11 11:20 PM | Andrea DifabioChief Legal Officer | Sale | 2,607 | $60.11 | $156.7K | 4,893(D) | View → |
| Mar 10, 2026 | Mar 11 11:20 PM | Ian MortimerDirector, PRESIDENT & CEO | Sale | 11,269 | $60.11 | $677.4K | 14,731(D) | View → |
| Mar 9, 2026 | Mar 11 11:20 PM | Ian MortimerDirector, PRESIDENT & CEO | Sale | 270,000 | $60.33 | $16.3M | 6,000(D) | View → |
Page 1 of 2
Next →
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | Mar 11 11:21 PM | Christopher John KenneyChief Medical Officer | Option Exercise | 7,500 | — | 0(D) | View → |
| Mar 9, 2026 | Mar 11 11:21 PM | Christopher John KenneyChief Medical Officer | Grant/Award | 7,500 | — | 7,500(D) | View → |
| Mar 9, 2026 | Mar 11 11:20 PM | Andrea DifabioChief Legal Officer | Option Exercise | 7,500 | — | 0(D) | View → |
| Mar 9, 2026 | Mar 11 11:20 PM | Andrea DifabioChief Legal Officer | Grant/Award | 7,500 | — | 7,500(D) | View → |
| Mar 9, 2026 | Mar 11 11:20 PM | Ian MortimerDirector, PRESIDENT & CEO | Option Exercise | 290,000 | $9.44 | 0(D) | View → |
| Mar 9, 2026 | Mar 11 11:20 PM | Ian MortimerDirector, PRESIDENT & CEO | Grant/Award | 20,000 | — | 20,000(D) | View → |
← Previous
Page 2 of 2